Dulskas Audrius, Poskus Tomas, Kildusiene Inga, Patasius Ausvydas, Stulpinas Rokas, Laurinavičius Arvydas, Mašalaitė Laura, Milaknytė Gabrielė, Stundienė Ieva, Venceviciene Lina, Strupas Kestutis, Samalavicius Narimantas E, Smailyte Giedre
Laboratory of Clinical Oncology, National Cancer Institute, 1 Santariskiu Str., LT-08406 Vilnius, Lithuania.
Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, M. K. Čiurlionio Str. 21/27, LT-03101 Vilnius, Lithuania.
Cancers (Basel). 2021 Mar 6;13(5):1129. doi: 10.3390/cancers13051129.
We aimed to report the results of the implementation of the National Colorectal Cancer (CRC) Screening Program covering all the country. The National Health Insurance Fund (NHIF) reimburses the institutions for performing each service; each procedure within the program has its own administrative code. Information about services provided within the program was retrieved from the database of NHIF starting from the 1 January 2014 to the 31 December 2018. Exact date and type of all provided services, test results, date and results of biopsy and histopathological examination were extracted together with the vital status at the end of follow-up, date of death and date of emigration when applicable for all men and women born between 1935 and 1968. Results were compared with the guidelines of the European Union for quality assurance in CRC screening and diagnosis. The screening uptake was 49.5% (754,061 patients) during study period. Participation rate varied from 16% to 18.1% per year and was higher among women than among men. Proportion of test-positive and test-negative results was similar during all the study period-8.7% and 91.3% annually. Between 9.2% and 13.5% of test-positive patients received a biopsy of which 52.3-61.8% were positive for colorectal adenoma and 4.6-7.3% for colorectal carcinoma. CRC detection rate among test-positive individuals varied between 0.93% and 1.28%. The colorectal cancer screening program in Lithuania coverage must be improved. A screening database is needed to systematically evaluate the impact and performance of the national CRC screening program and quality assurance within the program.
我们旨在报告覆盖全国的国家结直肠癌（CRC）筛查计划的实施结果。国家健康保险基金（NHIF）会向提供每项服务的机构报销费用；该计划中的每个程序都有其自己的行政代码。从NHIF数据库中检索了2014年1月1日至2018年12月31日期间该计划内提供的服务信息。提取了所有提供服务的准确日期和类型、检测结果、活检和组织病理学检查的日期及结果，以及所有1935年至1968年出生的男性和女性在随访结束时的生命状态、死亡日期和移民日期（如适用）。将结果与欧盟CRC筛查和诊断质量保证指南进行了比较。研究期间筛查接受率为49.5%（754,061名患者）。参与率每年从16%到18.1%不等，女性高于男性。在整个研究期间，检测阳性和检测阴性结果的比例相似，每年分别为8.7%和91.3%。9.2%至13.5%的检测阳性患者接受了活检，其中52.3% - 61.8%为结直肠腺瘤阳性，4.6% - 7.3%为结直肠癌阳性。检测阳性个体中的CRC检出率在0.93%至1.28%之间。立陶宛的结直肠癌筛查计划覆盖范围必须得到改善。需要一个筛查数据库来系统地评估国家CRC筛查计划的影响和绩效以及该计划内的质量保证。
